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Introduction
Patients with coronavirus disease 2019 (COVID-19) 
present with a broad spectrum of neurological disor-
ders whose features have been described in numer-
ous reports since the beginning of the global pandemic 
[1–5]. The incidence and prevalence of these disorders 
range from 3.5% to 84% among patients with COVID-19 
[2, 5, 6], with neurological symptoms ranging from mild 
(e.g., anosmia) to severe (e.g., encephalopathy, stroke) 
[1, 3]. A global community of researchers and clinicians 
has mobilized in an effort to elucidate the pathophysi-
ological mechanisms underlying neurological injury in 
patients with COVID-19. These mechanisms include 
hypoxia [7], inflammation [3], hypercoagulability [3], 
endothelial infection by the severe acute respiratory syn-
drome coronavirus 2 (SARS-CoV-2) [8], autoimmunity, 
and possibly encephalitis due to direct viral infection of 
the central nervous system by SARS-CoV-2 [9]. How-
ever, fundamental questions about pathophysiology and 
mechanisms of recovery remain, hampering our ability 
to diagnose, prognosticate, and treat patients with neuro-
logical disorders associated with COVID-19.
In response to the urgent need to advance knowledge 
about the many neurological disorders associated with 
COVID-19, there is growing recognition that inter-
national scientific collaboration is essential [10–13]. 
A coordinated global effort can accelerate the pace of 
discovery in COVID-19-related neurological disor-
ders, enabling timely translation into clinical practice. 
Accordingly, multiple large-scale studies were launched 
in the spring of 2020 to study COVID-19 neurological 
disorders, including the CoroNerve Study Group [4], the 
Italian Society of Neurology’s NEUROCOVID study [14], 
the James S. McDonnell Foundation’s COVID-19 Recov-
ery of Consciousness Consortium [15], the European 
Academy of Neurology’s EANCore project [10, 16], the 
Latin American Brain Injury Consortium (LABIC) [17], 
the Prospective Observational Study of Subarachnoid 
hemorrhage and IntracereBral hemorrhage patients in 
Latin America (POSSIBLE) network’s COVID-19 study 
[17], and the Global Consortium Study of Neurological 
Dysfunction in COVID-19 (GCS-NeuroCOVID) [17, 
18]. The EAN and the GCS-NeuroCOVID consortia have 
established a formal collaboration resulting in a global 
network that encompasses over 400 sites worldwide [12]. 
As part of that collaboration, the EAN and GCS-Neuro-
COVID consortia have committed to harmonizing their 
common data elements (CDEs) and data definitions to 
the extent possible, as indicated in their joint publication 
[12]. Many of these networks and consortia are repre-
sented in the Forum on Neurology and COVID-19 by the 
Brain Health Unit of the World Health Organization, a 
collaborative network of international clinicians and sci-
entists who participate in discussions about the clinical 
management, surveillance and research of COVID-19-re-
lated neurological manifestations and impact.
Central to these international efforts is the application 
of neuroimaging techniques, which play a key role in the 
diagnostic and prognostic evaluation of patients with 
COVID-19 neurological disorders and may also provide 
important insights into pathophysiological mechanisms. 
Neuroimaging can be challenging to perform in patients 
with COVID-19 because of safety precautions that are 
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necessary to protect other patients and hospital staff. This 
challenge is greatest in patients with COVID-19 critical 
illness and acute respiratory distress syndrome (ARDS), 
many of whom are too unstable to travel to a computed 
tomography (CT) or magnetic resonance imaging (MRI) 
scanner. The first case report describing neuroimaging 
findings associated with severe COVID-19—in an adult 
patient who was comatose due to hemorrhagic leukoen-
cephalitis [19]—was not published until March 31, 2020, 
more than four months after the first cases of COVID-19 
were reported in Wuhan, China, highlighting the logisti-
cal challenges associated with COVID-19 neuroimaging.
As the global pandemic approaches the end of its first 
year, and as protocols for safe patient transport are more 
widely implemented, neuroimaging tests such as head 
CT and brain MRI are increasingly utilized in clinical 
care and in research studies of adult patients with neuro-
logical disorders from COVID-19, including in the acute, 
subacute and chronic phases. These studies have begun 
to reveal the structural and functional correlates of neu-
rological disorders in patients with COVID-19 [3, 20, 
21]. This is a topic of profound neuroscientific interest 
and clinical relevance, as evidenced by the more than 600 
citations of the first COVID-19 neuroimaging case report 
in less than six months [19], and by the publication of 
numerous articles about COVID-19 neuroimaging dur-
ing the pandemic’s first nine months [22, 23].
Development of harmonized and uniform data ele-
ments is now a key goal to facilitate the most useful data 
repositories for investigating neurological disorders in 
COVID-19 [13]. Experience with other neurological 
diseases has demonstrated the benefit of collecting data 
in a systematic and consistent way, an approach cham-
pioned by the National Institutes of Health (NIH) CDEs 
process, which provides CDEs for a range of diseases 
(https ://www.commo ndata eleme nts.ninds .nih.gov/). 
In order to facilitate a similar process for patients with 
neurological disorders in the setting of COVID-19, the 
GCS-NeuroCOVID group consulted widely to con-
struct consensus CDEs for neurological complications 
and sequelae of COVID-19. This CDE effort has three 
tiers of data collection. Tier 1 [17] is a minimal dataset, 
which typically fulfills registry-level data abstraction 
and is designed to avoid the need to collect identifi-
able patient data. Tier 2 represents the workhorse of 
data collection for global studies and provides a level of 
detail that would be available from institutions in most 
developed countries and many developing countries. 
Tier 3 represents even more specialized data collection 
by centers and investigators with expertise in a given 
area and would likely require custom-built data collec-
tion designed by the study group addressing a specific 
research question.
As part of the Tier 2 CDE development effort, GCS-
NeuroCOVID convened a work group to create CDEs for 
neuroimaging studies of adult patients with COVID-19. 
Our goal was to create neuroimaging CDEs with the fol-
lowing characteristics:
(1) Capable of capturing the broad spectrum of findings 
reported to date in adult patients with COVID-19;
(2) Adaptable based on emerging evidence that might be 
reported in the future, particularly as more patients 
are imaged in the chronic phase; and
(3) Feasible to implement in hospitals around the world.
Given the rapidly evolving landscape of COVID-19 
neuroimaging, the CDEs that we report here are intended 
as a starting point for further efforts by members of the 
international medical and scientific community, who can 
adapt and refine these proposed COVID-19 neuroimag-
ing CDEs as additional neuroimaging discoveries emerge. 
These CDEs should be collected in conjunction with 
other relevant GCS-NeuroCOVID CDEs characterizing 
clinical characteristics and outcomes in adult patients. 
Ultimately, we expect that these COVID-19 neuroimag-
ing CDEs will evolve with ongoing efforts to standard-
ize data acquisition and data sharing, with the goal of 
improving care and outcomes for patients with COVID-
19 neurological disorders globally.
Methods
CDE Development Meetings
A nine-member Neuroimaging Work Group was con-
vened as part of GCS-NeuroCOVID to develop neuroim-
aging CDEs for adult patients with COVID-19. The work 
group met weekly online from July 16 to October 8, 2020, 
with the goal of creating COVID-19 neuroimaging CDEs 
for Tier 2 of the GCS-NeuroCOVID project. Whereas 
Tier 1 of GCS-NeuroCOVID aimed to capture the fre-
quency of neuroimaging in patients with COVID-19, Tier 
2 aims to characterize relevant neuroimaging features.
Given that Tier 2 is planned as a multicenter, interna-
tional study of data acquired as part of clinical practice, 
we developed the Tier 2 CDEs to capture data from com-
monly available techniques (e.g., head CT and conven-
tional MRI), not from advanced imaging techniques such 
as functional MRI [21] or diffusion tensor imaging [24, 
25]. CDEs for advanced neuroimaging techniques will 
be developed to support future GCS-NeuroCOVID Tier 
3 studies conducted at centers that are able to prospec-
tively acquire such data.
Literature Review and Feature Classification
The GCS-NeuroCOVID Neuroimaging Work Group’s 
first task was to perform a comprehensive literature 
review of all studies published on COVID-19 neuroimag-
ing in the adult patient population. We used the search 
terms “COVID-19”, “neuroimaging”, “computed tomog-
raphy”, “CT”, “magnetic resonance imaging”, “MRI”, “CT 
Perfusion”, “MRI Perfusion”, “MRI spectroscopy”, “Posi-
tron Emission Tomography” and “PET” using the Pub-
Med database and the bioRxiv and medRxiv preprint 
servers. These database searches, performed between 
July 16 and October 8, 2020, were supplemented by 
knowledge of manuscripts listed on authoritative web-
sites (https ://blogs .bmj.com/jnnp/2020/05/01/the-neuro 
logy-and-neuro psych iatry -of-covid -19/). Manuscript 
selection was based on consensus review to optimize the 
diversity of imaging features represented.
After compiling imaging reports described in pub-
lished and preprint manuscripts, we organized data by 
imaging features, not by any presumed interpretive or 
diagnostic classification. For example, hypointensities 
detected on susceptibility-weighted imaging (SWI) were 
classified as such, not as microhemorrhages, given that 
these lesions can also represent microthrombi and/or 
air bubbles (e.g., in patients treated with extracorporeal 
membrane oxygenation). Similarly, hyperintense lesions 
on diffusion-weighted imaging (DWI) were classified as 
diffusion restriction (as long as there was corresponding 
hypointense signal on the apparent diffusion coefficient 
map), not as ischemic infarcts, given that these lesions 
can also be caused by seizures, brain tumors, abscesses 
and/or hypercellularity (e.g., in patients with infectious 
or para-infectious encephalitis). In short, we chose a 
feature-based approach to avoid making assumptions 
without firm evidence about the mechanisms by which 
COVID-19 affects the nervous system.
Adaptation of Established CDEs for Neuroimaging 
of COVID‑19
After completion of the literature review and classifica-
tion of the described imaging features, we reviewed exist-
ing neuroimaging CDEs commissioned by the NIH (https 
://commo ndata eleme nts.ninds .nih.gov). Our goal was to 
leverage these existing CDEs and, whenever possible, to 
use CDEs that were already defined according to estab-
lished standards. These previously published CDEs pro-
vide the benefit of user familiarity and prior vetting by 
neuroimaging experts [26–28].
Consistent with previously published CDEs, we organ-
ized the COVID-19 neuroimaging CDEs into case report 
forms (CRFs) by imaging techniques. Techniques were 
eligible for inclusion based on prespecified criteria: (1) 
routine acquisition of the technique in clinical practice; 
and (2) at least one publication describing the clinical 
application of the technique in patients with COVID-19.
Importantly, most previously published neuroimag-
ing CDEs describe specific diagnostic syndromes (e.g., 
ischemic stroke, intracerebral hemorrhage). Thus, 
although our overall goal was to use a feature-based 
approach to COVID-19 neuroimaging CDEs, we include 
previously published CDEs in “Syndromic CDEs” sec-
tions of the CRFs. Our rationale for including these “Syn-
dromic CDEs” sections is that the emerging literature on 
COVID-19 neurological disorders includes descriptions 
of patients with well-characterized neurological syn-
dromes, such as ischemic stroke [3], even if the mecha-
nistic association between the syndromes and COVID-19 
is unclear.
Proposal for New Feature‑Based COVID‑19 Neuroimaging 
CDEs
For the neuroimaging features described in COVID-19 
publications that were not accounted for by previously 
published CDEs, we created new descriptive CDEs based 
on consensus opinion. These descriptive CDEs are listed 
in separate sections titled “Feature-based CDEs” within 
the CRFs. By organizing the COVID-19 neuroimaging 
CDEs into complementary “Syndromic CDEs” and “Fea-
ture-based CDEs” sections, we aimed to provide investi-
gators with the flexibility to thoroughly characterize all 
neuroimaging findings, regardless of whether they can fit 
within previously described neurological syndromes.
Classifying the Pathophysiologic Association of Imaging 
Findings with COVID‑19
We also provide investigators with an opportunity to 
enter data about presumed mechanisms of neurological 
injury and their relatedness to COVID-19. At the end of 
each “Syndromic CDEs” section and each “Feature-based 
CDEs” section of a CRF, we created new CDEs pertain-
ing to the presumed cause of the imaging findings. Spe-
cifically, we provide investigators with an opportunity 
to indicate whether the findings are associated with 
COVID-19. Such data will enable assessment of the inter-
national community’s interpretation of newly observed 
imaging findings, while also providing hypothesis-gener-
ating data for future studies.
CDE Classification as Core or Supplemental
All CDEs were classified as “core” or “supplemental” 
based on the consensus opinion of the Work Group. 
Given that the goal of the Tier 2 GCS-NeuroCOVID 
study is to identify common neuroimaging features in 
patients with neurological disorders related to COVID-
19, we assigned the “core” designation to all CDEs that 
documented the presence or absence of those features. 
We assigned the “supplemental” designation to CDEs 
that characterize the neuroanatomic distribution and 
chronicity of imaging features, details which may aid 
neuroscientific and translational research. Limiting the 
number of core CDEs was intended to reduce the bur-
den of data entry, which can lead to incomplete CRFs and 
reduced participation in multicenter international tri-
als. This trade-off between thoroughness and feasibility 
is particularly relevant during the COVID-19 pandemic, 
when many clinicians and researchers are strained for 
time and resources.
Results
Adaptation of Previously Proposed CDEs to COVID‑19
The neuroimaging CDEs previously proposed by the 
NIH that were most relevant to COVID-19 included 
those developed for ischemic stroke [27], traumatic brain 
injury [26] and subarachnoid hemorrhage [28]. Based on 
these previously developed CDEs, we created six CRFs, 
each representing a neuroimaging technique: (1) head 
CT; (2) conventional MRI; (3) CT perfusion; (4) MR 
perfusion; (5) MR spectroscopy; and (6) positron emis-
sion tomography (PET). An overview of the six CRFs is 
provided in Table 1. Of note, we limited the PET CDEs 
to studies obtained in standard clinical practice, such as 
FDG- and 15O-PET. CDEs for PET studies utilizing addi-
tional radioligands will be added in Tier 3. Given limited 
prior reports on neuroimaging studies utilizing cerebral 
angiography [29] and spinal cord imaging [30], CDEs for 
these modalities will also be added in Tier 3.
Neuroimaging Features in Adult Patients with Neurological 
Disorders Related to COVID‑19
The complete list of neuroimaging features that we iden-
tified as of October 8, 2020 are provided in Table 2 and 
listed in the “Feature-based CDEs” sections of the six 
CRFs that we release with this manuscript.
Dissemination of CDEs for COVID‑19 Neuroimaging
We release version 1.0 of the proposed neuroimaging 
CDEs for adult patients with COVID-19 as a set of six 
CRFs (https ://zenod o.org/recor d/44048 55). For each 
CRF, we created an abbreviated version that contains 
core CDEs and a comprehensive version that contains 
core and supplemental CDEs.
We encourage feedback regarding modifications to 
the CDEs, which can be submitted via email to the cor-
responding author. We are committed to an adaptive 
approach based on emerging evidence, with rapid distri-
bution of modifications in real time using online scien-
tific portals.
Discussion
As the international community looks toward the next 
stage of the COVID-19 pandemic, there is growing rec-
ognition that global multicenter collaboration, data 
standardization and data sharing are essential to advance 
knowledge and improve care for patients with neuro-
logical disorders caused by COVID-19. To support this 
Table 1 Organization of common data elements into case report forms
The COVID-19 neuroimaging common data elements (CDEs) proposed for Tier 2 of the GCS-NeuroCOVID study are organized into six case report forms, each 
representing an imaging modality (columns): head computed tomography (CT), conventional magnetic resonance imaging (MRI), CT perfusion, magnetic resonance 
(MR) perfusion, MR spectroscopy, and positron emission tomography (PET). Within each case report form, CDEs are organized into sections (rows)
CT MRI Perfusion CT/MR MR spectroscopy PET
Patient Information Time since symptom onset, time since COVID‑19 diagnosis
Clinical Indication Scan purpose, neurological symptoms at time of scan
Technical Information Scanner, sequences
Imaging Result Normal, abnormal (acute), abnormal (chronic), abnormal (acute and chronic), indeterminate
Syndromic CDEs Stroke, hemorrhage, hydrocephalus
Feature‑based CDEs Signal characteristics Metabolites Tracer uptake
Mechanism Associated, not associated, or uncertain association with COVID‑19
Table 2 Feature-based Common Data Elements
CBF cerebral blood flow, CDE common data element, CT computed tomography, 
MTT mean transit time, MRI magnetic resonance imaging, TMax time to 
maximum
Case report form Feature‑based CDEs
CT Hypodensity, hyperdensity, enhancement
MRI Decreased volume, increased volume, diffu‑
sion restriction, T2‑weighted hyperintensity, 
susceptibility‑weighted or
T2*‑weighted hypointensity, enhancement, 
cystic changes
CT Perfusion CBF, MTT, Time to peak, or TMax abnormalities
MR Perfusion
MR Spectroscopy Metabolite abnormalities: N‑acetyl‑ aspartate, 
Choline, Creatine, Myo‑inositol, Lactate, 
Glutamine/glutamate
PET Localization of tracer uptake
effort, we developed and now disseminate proposed 
CDEs for COVID-19 neuroimaging of adult patients. We 
designed these CDEs to be widely accessible and easy to 
implement at both academic medical centers and com-
munity hospitals. The COVID-19 neuroimaging CDEs 
leverage previous CDE efforts supported by the NIH, 
ensuring consistency with established standards for data 
acquisition. Newly proposed CDEs specific to COVID-
19 were added based on a review of COVID-19 neuro-
imaging studies published during the first 10 months of 
the global pandemic. All COVID-19 CDEs, organized in 
6 technique-specific CRFs, are available at https ://zenod 
o.org/recor d/44048 55.
The CDEs proposed here are feature-based, a strategy 
intended to avoid presumptions about the mechanisms 
by which COVID-19 affects the nervous system. At this 
stage of the pandemic, given an incomplete understand-
ing of disease pathophysiology, we believe that neuroim-
aging data are most likely to enable knowledge creation if 
they are categorized using CDEs that are descriptive and 
not diagnostic in nature. Diagnostic categorizations can 
then be proposed, and revised, as more becomes known 
about how SARS-CoV-2 affects the nervous system. We 
therefore envision this CDE development effort as a 
dynamic process with rapid revisions reflecting ongoing 
progress in the field of COVID-19 neuroimaging. Only 
with a comprehensive, global commitment to data stand-
ardization and data sharing can the international com-
munity advance knowledge and improve care for patients 
with neurological disorders associated with COVID-19.
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